This possibility is intriguing for translation to clinical settings since in ovarian carcinoma patients tumor lesions have been shown to specifically recruit CD4+CD25+Foxp3+ T-reg cells, while tumor-infiltrating Th-17 cells recruit effector T cells to the tumor microenvironment and their levels positively correlate with clinical outcome. The gene discussed is FOXP3; the disease is neoplasm.